Literature DB >> 745018

L-deprenyl treatment of on-off phenomena in Parkinson's disease.

U K Rinne, T Siirtola, V Sonninen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 745018     DOI: 10.1007/bf01246962

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


× No keyword cloud information.
  16 in total

1.  On the occurrence of homovanillic acid in brain and cerebrospinal fluid and its determination by a fluorometric method.

Authors:  N E ANDEN; B E ROOS; B WERDINIUS
Journal:  Life Sci (1962)       Date:  1963-07

2.  5-Hydroxyindoles in human cerebrospinal fluids.

Authors:  G W ASHCROFT; D F SHARMAN
Journal:  Nature       Date:  1960-06-25       Impact factor: 49.962

Review 3.  Recent advances in research on Parkinsonism.

Authors:  U K Rinne
Journal:  Acta Neurol Scand Suppl       Date:  1978

4.  Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.

Authors:  U K Rinne; V Sonninen; T Sirtola
Journal:  Z Neurol       Date:  1972

5.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

6.  [Experimental results of the combined treatment of parkinsonism using L-DOPA and a decarboxylase inhibitory agent (Ro 4-4602)].

Authors:  W Birkmayer
Journal:  Wien Klin Wochenschr       Date:  1969-09-26       Impact factor: 1.704

7.  Treatment of parkinsonism with levodopa.

Authors:  M D Yahr; R C Duvoisin; M J Schear; R E Barrett; M M Hoehn
Journal:  Arch Neurol       Date:  1969-10

8.  Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.

Authors:  W Birkmayer; P Riederer; L Ambrozi; M B Youdim
Journal:  Lancet       Date:  1977-02-26       Impact factor: 79.321

9.  Success and problems of long-term levodopa therapy in Parkinson's disease.

Authors:  C D Marsden; J D Parkes
Journal:  Lancet       Date:  1977-02-12       Impact factor: 79.321

10.  Deprenyl in Parkinson's disease.

Authors:  A J Lees; K M Shaw; L J Kohout; G M Stern; J D Elsworth; M Sandler; M B Youdim
Journal:  Lancet       Date:  1977-10-15       Impact factor: 79.321

View more
  11 in total

Review 1.  Parkinson's disease.

Authors:  E C Wolters; D B Calne
Journal:  CMAJ       Date:  1989-03-01       Impact factor: 8.262

Review 2.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 3.  The pharmacology of Parkinson's disease: basic aspects and recent advances.

Authors:  M Da Prada; H H Keller; L Pieri; R Kettler; W E Haefely
Journal:  Experientia       Date:  1984-11-15

Review 4.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

5.  Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice.

Authors:  A Fredriksson; T Archer
Journal:  J Neural Transm Gen Sect       Date:  1995

6.  Effects of L-deprenyl on human growth hormone secretion.

Authors:  M Koulu; R Lammintausta
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

7.  Deprenyl in Parkinson disease: personal experience.

Authors:  P Giovannini; M P Grassi; G Scigliano; I Piccolo; P Soliveri; T Caraceni
Journal:  Ital J Neurol Sci       Date:  1985-06

8.  The neuropharmacological profile of N-methyl-N-propargyl-2-aminotetralin: a potent monoamine oxidase inhibitor.

Authors:  B Hazelhoff; J B De Vries; D Dijkstra; W de Jong; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-07       Impact factor: 3.000

Review 9.  Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.

Authors:  E H Heinonen; V Myllylä
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

10.  Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.

Authors:  M Schachter; C D Marsden; J D Parkes; P Jenner; B Testa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-11       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.